The European Commission granted Marketing Authorisation for Vueway® (gadopiclenol) in the European Union

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Bracco-EU-Autho

More Like This

PR Newswire associated0

Vueway® (Gadopiclenol) Receives Positive CHMP Opinion

PR Newswire associated0

The European Commission extended the Marketing Authorisation for Vueway® (gadopiclenol) in the European Union for use in pediatric patients under 2 years of age

PR Newswire associated0

The CHMP adopted a positive opinion for Vueway® (gadopiclenol) for its use in pediatric patients under 2 years of age

PR Newswire associated0

Guerbet announces marketing authorisation approval of Elucirem™ (Gadopiclenol) in the European Union

PR Newswire associated0

New indication in children from birth for Guerbet's half-dose GBCA, Elucirem™ (Gadopiclenol) approved by European Commission

First-in-human contrast enhanced MRI images with GE HealthCare's mangaciclanol

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents

PR Newswire associated0

Bracco Marks Major Global Milestone with U.S. FDA 510(k) Clearance and Health Canada Authorization for VueJect®, the First Dedicated Ultrasound Contrast Delivery System to Support Cardiology Imaging

A radiologist looking at MRI exam images (Photo: Business Wire)

GE HealthCare Announces Phase I Results for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent